T Hasegawa1, S Hayashida2, E Kondo3, Y Takeda4, H Miyamoto5, Y Kawaoka6, N Ueda7, E Iwata8,9, H Nakahara10, M Kobayashi11, S Soutome2, S I Yamada3, I Tojyo4, Y Kojima6, M Umeda2, S Fujita4, H Kurita3, Y Shibuya5, T Kirita7, T Komori8. 1. Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. hasetaku@med.kobe-u.ac.jp. 2. Department of Clinical Oral Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. 3. Department of Dentistry and Oral Surgery, Shinshu University School of Medicine, Matsumoto, Japan. 4. Department of Oral and Maxillofacial Surgery, Wakayama Medical University, Wakayama, Japan. 5. Department of Oral Maxillofacial Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. 6. Department of Dentistry and Oral Surgery, Kansai Medical University, Hirakata, Japan. 7. Department of Oral and Maxillofacial Surgery, Nara Medical University, Kashihara, Japan. 8. Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. 9. Department of Oral and Maxillofacial Surgery, Kakogawa Central City Hospital, Kakogawa, Japan. 10. Department of Oral and Maxillofacial Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan. 11. Department of Oral and Maxillofacial Surgery, Shin-Suma General Hospital, Kobe, Japan.
Abstract
Root amputation, immunosuppressive therapy, mandibular tooth extraction, pre-existing inflammation, and longer duration of treatment with bone-modifying agents were significantly associated with an increased risk of medication-related osteonecrosis of the jaw. Hopeless teeth should be extracted without drug holiday before the development of inflammation in cancer patients receiving high-dose bone-modifying agents. INTRODUCTION: No studies have comprehensively analyzed the influence of pre-existing inflammation, surgical procedure-related factors such as primary wound closure, demographic factors, and drug holiday on the incidence of medication-related osteonecrosis of the jaw (MRONJ). The purpose of this study was to retrospectively investigate the relationships between these various factors and the development of MRONJ after tooth extraction in cancer patients receiving high-dose bone-modifying agents (BMAs) such as bisphosphonates or denosumab. METHODS: Risk factors for MRONJ after tooth extraction were evaluated with univariate and multivariate analyses. The following parameters were investigated in all patients: demographics, type and duration of BMA use, whether BMA use was discontinued before tooth extraction (drug holiday), the duration of such discontinuation, the presence of pre-existing inflammation, and whether additional surgical procedures (e.g., incision, removal of bone edges, root amputation) were performed. RESULTS: We found that root amputation (OR = 22.62), immunosuppressive therapy (OR = 16.61), extraction of mandibular teeth (OR = 12.14), extraction of teeth with pre-existing inflammation, and longer duration (≥ 8 months) of high-dose BMA (OR = 7.85) were all significantly associated with MRONJ. CONCLUSIONS: Tooth extraction should not necessarily be postponed in cancer patients receiving high-dose BMA. The effectiveness of a short-term drug holiday was not confirmed, as drug holidays had no significant impact on MRONJ incidence. Tooth extraction may be acceptable during high-dose BMA therapy until 8 months after initiation.
Root amputation, immunosuppressive therapy, mandibular tooth extraction, pre-existing inflammation, and longer duration of treatment with bone-modifying agents were significantly associated with an increased risk of medication-related osteonecrosis of the jaw. Hopeless teeth should be extracted without drug holiday before the development of inflammation in cancerpatients receiving high-dose bone-modifying agents. INTRODUCTION: No studies have comprehensively analyzed the influence of pre-existing inflammation, surgical procedure-related factors such as primary wound closure, demographic factors, and drug holiday on the incidence of medication-related osteonecrosis of the jaw (MRONJ). The purpose of this study was to retrospectively investigate the relationships between these various factors and the development of MRONJ after tooth extraction in cancerpatients receiving high-dose bone-modifying agents (BMAs) such as bisphosphonates or denosumab. METHODS: Risk factors for MRONJ after tooth extraction were evaluated with univariate and multivariate analyses. The following parameters were investigated in all patients: demographics, type and duration of BMA use, whether BMA use was discontinued before tooth extraction (drug holiday), the duration of such discontinuation, the presence of pre-existing inflammation, and whether additional surgical procedures (e.g., incision, removal of bone edges, root amputation) were performed. RESULTS: We found that root amputation (OR = 22.62), immunosuppressive therapy (OR = 16.61), extraction of mandibular teeth (OR = 12.14), extraction of teeth with pre-existing inflammation, and longer duration (≥ 8 months) of high-dose BMA (OR = 7.85) were all significantly associated with MRONJ. CONCLUSIONS: Tooth extraction should not necessarily be postponed in cancerpatients receiving high-dose BMA. The effectiveness of a short-term drug holiday was not confirmed, as drug holidays had no significant impact on MRONJ incidence. Tooth extraction may be acceptable during high-dose BMA therapy until 8 months after initiation.
Entities:
Keywords:
Bisphosphonate; Denosumab; Discontinuation; Drug holiday; MRONJ
Authors: Cesar A Migliorati; Deborah Saunders; Michael S Conlon; Hanne Kleven Ingstad; Paul Vaagen; Mitzi J Palazzolo; Bente B Herlofson Journal: J Am Dent Assoc Date: 2013-04 Impact factor: 3.634
Authors: Kristine E Ensrud; Elizabeth L Barrett-Connor; Ann Schwartz; Arthur C Santora; Douglas C Bauer; Shailaja Suryawanshi; Adrianne Feldstein; William L Haskell; Marc C Hochberg; James C Torner; Antonio Lombardi; Dennis M Black Journal: J Bone Miner Res Date: 2004-03-29 Impact factor: 6.741
Authors: T Hasegawa; N Ueda; S I Yamada; S Kato; E Iwata; S Hayashida; Y Kojima; M Shinohara; I Tojo; H Nakahara; T Yamaguchi; T Kirita; H Kurita; Y Shibuya; S Soutome; M Akashi Journal: Osteoporos Int Date: 2021-05-17 Impact factor: 4.507
Authors: Parish P Sedghizadeh; Shuting Sun; Allan C Jones; Esmat Sodagar; Philip Cherian; Casey Chen; Adam F Junka; Jeffrey D Neighbors; Charles E McKenna; R Graham G Russell; Frank H Ebetino Journal: Bone Date: 2021-03-20 Impact factor: 4.626
Authors: Sven Otto; Suad Aljohani; Riham Fliefel; Sara Ecke; Oliver Ristow; Egon Burian; Matthias Troeltzsch; Christoph Pautke; Michael Ehrenfeld Journal: Medicina (Kaunas) Date: 2021-05-09 Impact factor: 2.430